Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT03174405 Completed - Clinical trials for Metastatic Colorectal Cancer

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

AVETUX
Start date: July 17, 2017
Phase: Phase 2
Study type: Interventional

AVETUX is a single arm multicentric phase II investigator initiated trial conducted by the Arbeitsgemeinschaft Internistische Onkologie (AIO) in 11 German sites in patients with previously untreated RAS/BRAF wildtype mCRC independent of MSI status.

NCT ID: NCT03168139 Completed - Clinical trials for Metastatic Colorectal Cancer

Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer

Keynote-559
Start date: April 18, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to show that the type, number and/or distribution of tumor metastases infiltrating immune cells such as cytotoxic T cells and/or the cytokine signature in the tumor metastases can be modulated by treatment with olaptesed pegol and to explore safety, tolerability and efficacy of olaptesed pegol in combination with pembrolizumab as a basis for subsequent studies in combination with immunotherapies, in particular checkpoint inhibitors.

NCT ID: NCT03130634 Completed - Clinical trials for Metastatic Colorectal Cancer

The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment

Start date: April 2016
Phase: Phase 4
Study type: Interventional

Primary objectives: Use both listed and relatively safe drug, Silymarin,s to improve the intestinal side effect of the patients undergoing FOLFIRI chemotherapy.

NCT ID: NCT03122509 Completed - Clinical trials for Metastatic Colorectal Cancer

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Start date: April 24, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of two investigational drugs (drugs that are not currently approved by the FDA) given in combination with radiation therapy or ablation.

NCT ID: NCT03081494 Completed - Clinical trials for Metastatic Colorectal Cancer

Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Start date: June 9, 2017
Phase: Phase 1
Study type: Interventional

This was a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study assessed primarily the safety and tolerability of PDR001 in combination with regorafenib.

NCT ID: NCT03043950 Completed - Clinical trials for Metastatic Colorectal Cancer

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)

VALIDATE
Start date: January 25, 2017
Phase:
Study type: Observational

A safety and efficacy study of first line therapy with Vectibix® in combination with FOLFIRI or FOLFOX to validate a prognostic score in adult patients with RAS wild-type metastatic colorectal cancer in a real world setting (VALIDATE)

NCT ID: NCT03031691 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Start date: January 2017
Phase: Phase 1
Study type: Interventional

A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination with Chemotherapy for Subjects with Previously Treated Metastatic Colorectal Cancer.

NCT ID: NCT03010722 Completed - Clinical trials for Metastatic Colorectal Cancer

Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy

PROSPECT-R
Start date: January 2015
Phase:
Study type: Observational

This is a single centre prospective biological translational research study involving the collection of tumour tissue, blood samples and clinical data from patients being treated with regorafenib for metastatic Colorectal Cancer (mCRC) at the Royal Marsden Hospital. Patients will be eligible for the study if they have a histological diagnosis of CRC, are refractory to standard available therapies with palliative intent for mCRC, have received prior treatment with at least one anti-VEGF antibody and chemotherapy drugs including fluorouracil (5FU) or capecitabine, oxaliplatin and irinotecan, and patients have RAS mutant tumours.

NCT ID: NCT03008499 Completed - Clinical trials for Metastatic Colorectal Cancer

High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer

Start date: December 1, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is the safety and efficacy of high-activity natural killer immunotherapy to small metastases of colorectal cancer.

NCT ID: NCT02994888 Completed - Clinical trials for Metastatic Colorectal Cancer

PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer

PROSPECT-C
Start date: November 2012
Phase: N/A
Study type: Observational

PROSPECT-C is a phase II study investigating the molecular markers of response or resistance to anti-epidermal growth factor receptor (EGFR) antibodies.